ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
Shares of ImmuCell Corporation ICCC have gained 6.5% since the company reported earnings for the fourth quarter of 2024. This compares with the S&P 500 index’s 0.6% dip over the same time frame. Over the past month, the stock has lost 0.4% compared with the S&P 500’s 2.2% decline. Strong Revenue Growth & Improved Profitability ...









